Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases

The dysregulation of NLRP3 inflammasome can cause uncontrolled inflammation and drive the development of a wide variety of human diseases, but the medications targeting NLRP3 inflammasome are not available in clinic. Here, we show that tranilast (TR), an old anti‐allergic clinical drug, is a direct...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yi, Jiang, Hua, Chen, Yun, Wang, Xiaqiong, Yang, Yanqing, Tao, Jinhui, Deng, Xianming, Liang, Gaolin, Zhang, Huafeng, Jiang, Wei, Zhou, Rongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887903/
https://www.ncbi.nlm.nih.gov/pubmed/29531021
http://dx.doi.org/10.15252/emmm.201708689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887903/
https://www.ncbi.nlm.nih.gov/pubmed/29531021
http://dx.doi.org/10.15252/emmm.201708689

Ejemplares similares